Trees Don’t Grow to the Sky — Why 7 to 20% Revenue Growth Is the Sweet Spot
December 10, 2025
10 min read
Trees Don't Grow to the Sky — Why 7 to 20% Revenue Growth Is the Sweet Spot
Sales growth is at the heart of every business. But not all growth is created equal. Too little, and the business stagnates. Too much, and volatility — and hype — punish investors. The sweet spot? 7 to 20% revenue growth. That's where compounding and discipline meet. Our original analysis for The Market NZZ — plus the in-depth investor view.
In 30 seconds — the core thesis
- The sweet spot is 7–20% revenue growth. Below 7%, the business lags global indices. Above 20% is statistically unsustainable — Mauboussin's data shows: among companies starting at $50B+ in revenue, not a single one sustained 20% growth for a decade.
- Today quality stocks are undervalued, speculative tech overvalued. A market split like 1999. Unprofitable and revenue-less firms (nuclear fusion, quantum) fly. Solid compounders underperform. That's the quality anomaly — an opportunity that appears roughly once a decade.
- Discipline pays because math always beats mood. Dotcom era: Berkshire Hathaway looked painfully boring while tech names doubled on press releases. Then math caught up with mood. The pattern repeats.
The original analysis — the opening
«The big money is not in the buying and selling. But in the waiting.»
— Charlie Munger, architect of Berkshire Hathaway (1924–2023)
Sales growth is the most important value driver for companies. But just as important — if not more — is the range of sales growth over long periods of time.
Too little growth, and both the business and stock price stagnate. No one pays attention. Too much growth, on the other hand, attracts investors — but the stock price often jumps ahead, pricing in a rosy future long before it arrives. That high-growth zone is exciting, full of great stories. But high growth comes with high volatility, bouts of excessive optimism followed by excessive pessimism. And underneath it all lies the simple truth: trees don't grow to the sky.
The range to focus on is 7 to 20% revenue growth. Below 7% is insufficient. Above 20% is unsustainable.
→ Read the full article on The Market by NZZ
Chart 1: Sales growth is the key driver of long-term stock performance
Source: BCG Analysis, Morgan Stanley Research — Top-Quartile S&P 500, 1990–2009
01Why 7% — the floor of relevance
The floor is relatively straightforward. Over long stretches of time, stock prices follow the trajectory of the underlying business. If a company can grow its top line sustainably at roughly 7%, its share price will compound in the same neighbourhood.
History backs this up: around 7% is the long-term average of companies in global equity indices. Over the past century, the MSCI World delivered roughly 7 to 10% annual returns in dollars. Swiss equities — not exactly famous for adrenaline — delivered a steady 7.7% in Swiss francs over nearly a century (Pictet study).
The 7% threshold is no accident
A 7% floor is simply the level at which a business begins to keep up with global markets. Anything below, and the fuel for sustainable outperformance is typically missing. But be careful: 7% is the minimum, not the goal. A company that combines 20 years of 7% organic growth with disciplined high-ROIC reinvestment often beats the market clearly — because compounding works company-specific, while the index gets dampened by rotation and averaging.
02Why 20% — the ceiling of physics
This is where things get interesting. Michael Mauboussin and co-authors studied revenue growth for the 1,000 largest global companies going back to 1950. Their conclusion: it is extraordinarily rare for a company — especially a large one — to grow revenue at 20% or more for a full decade.
Mauboussin's base rates — 10-year growth above 20%
3%
of companies starting at $1.25–2.0B in revenue achieved 20%+ over 10 years
0
companies starting at ≥ $50B revenue managed it — not one single one since 1950
The Law of Large Numbers is not a suggestion. It is a gravitational force. Once a company reaches real scale, the 20% dream evaporates entirely.
Source: The Base Rate Book — Sales Growth, Credit Suisse, Mauboussin
This leads to four central arguments for the 7–20% sweet spot — where the compounding magic happens:
- Growth must earn its keep. Growth only matters when it creates value, not when it destroys it. A company must earn returns on invested capital (ROIC) above the cost of that capital; otherwise, even rapid sales growth is just a more elegant way of lighting money on fire. Sustainable compounders grow profitably — not aggressively.
- Durability beats drama. The world loves flashy hypergrowth stories. Yet investors who compound wealth over decades tend to favor the opposite: companies that deliver steady, repeatable growth paired with consistently high profitability. 7% for 20 years beats 25% for two years followed by inevitable disappointment.
- The sweet spot is no accident. Many quality-focused investment frameworks anchor themselves — explicitly or implicitly — in a mid-range growth zone. In this band, growth is both meaningful and sustainable. Companies here compound cash flows without stretching the limits of physics, optimism, or capital markets.
- Valuation vs. sustainability. The 20% ceiling is a guardrail against risk. When growth inevitably slows, the premium P/E multiple collapses — often destroying years of underlying earnings growth. The result: disappointing stock returns.
The three zones of revenue growth
< 7%
Stagnation
7 – 20%
Sweet Spot
> 20%
Hype Trap
Left of the sweet spot, the business stagnates. Right of it, boom-bust cycles and multiple contraction loom. In between lies the zone where discipline and compounding work together.
How this 7–20% zone interacts concretely with the Steve-Jobs top-line × margin-expansion logic is explored in our companion «Focus on the Top Line, the Bottom Line Will Follow». Both articles address the same phenomenon from different angles: growth as driver and risk source.
03Today's market — narrative hype and quality anomaly
The market's attention has wandered. Again. Markets are always driven by narratives — stagflation in the Seventies lifting energy stocks, Japan-mania in the Eighties, dotcom companies with clicks but no cash in the Nineties, China's industrial rise in the 2000s. Each era had its obsession, readable in the top-ten companies at the start of each decade.
And today? Artificial intelligence — flanked by nuclear energy, quantum computing, infrastructure, rare earths. The result is a market split cleanly in two: stocks associated with the hot themes — and everything else.
The extreme 2025 market split
Unprofitable companies are among the strongest performers of the year. More extreme still: companies with no revenue at all — nuclear or quantum darlings — have outperformed nearly every other group, often by a factor of two. And while AI can have a modest seat in a portfolio, fluff has none. «It's all about AI — or fluff» — and the fluff is driving the bids.
For quality investors this is frustrating — but actually good news. When the manic-depressive Mr. Market shifts focus from fundamentals to the next big narrative, something interesting happens: great businesses quietly get cheaper. Stock prices start lagging business performance. Market commentators call this a rotation. What it really means is that quality names underperform — despite intact fundamentals.
Right now, wonderful quality companies are trading at more-than-fair prices — a rare anomaly that appears only once a decade or so (dotcom 1999, post-2008). On the other side, many fair companies trade at more-than-wonderful prices. As Buffett put it, paraphrased: better a wonderful company at a fair price than a fair company at a wonderful one. History shows: quality businesses, grounded in strong fundamentals, eventually see prices catch up. Of course, the long run requires patience.
04The dotcom parallel — why math always wins
The title is a cliché: history does not repeat, but it often rhymes. Probably why it's true. Mr. Market's chase for the hottest narrative cuts both ways: sharply up, sharply down.
Look at today's market darlings. The enthusiasm feels familiar — a shade of déjà vu from the dotcom boom, when story stocks levitated far above reality before gravity reminded investors that narratives don't pay bills.
Warren Buffett famously sat out the dotcom frenzy. He missed one of the strongest bull markets in recent history. Berkshire Hathaway looked painfully dull while others doubled on press releases and promises. But he stayed committed to his philosophy: own businesses that can compound at high rates within a sustainable range. And eventually — as it always does — the math caught up with the mood. Business quality and fundamentals won.
The Novo Nordisk warning
If you are riding high-growth names today, keep an eye on the exit door. Perfectly aligned market structures never stay perfectly aligned. Simple trend-following tools — like long-term moving averages — can help avoid getting caught when the music stops. And remember: when trees bend, they correct on average 72% and need five years to recover. Cue: Novo Nordisk. This is not abstract. This is the real price risk behind the 20% ceiling.
05Three scenarios for the quality anomaly
No one can time the market. But we can describe three plausible paths for how the current market split resolves over the next 18–24 months:
Bull Case
The quality anomaly resolves quickly — compounders outperform meaningfully
A correction in speculative themes (quantum, nuclear fusion, revenue-less tech) frees up capital that flows back into fundamental quality companies. Compounder multiples expand back to historical ranges. 15–25 percentage points of outperformance vs. the broad market over 18 months is plausible in this scenario. The historical parallel is 2000–2003, when defensive quality names clearly beat the broad market.
Base Case
The split persists — patience is tested, compounders keep delivering
The narrative dynamic lasts longer than expected. Quality stocks stay in the shadow another 6–12 months while tech darlings continue their multiple expansion. Then selective rotation kicks in — triggered by a first earnings warning from a prominent hype name. Compounders catch up gradually. Those who held discipline are rewarded over 24 months — but not dramatically. Our base case.
Bear Case
The split deepens — compounders underperform for another 18 months
The narrative dynamic deepens. AI-driven optimism attracts further capital flows into speculative segments. Quality stocks fall further out of favor — despite intact fundamentals. Investors who cannot hold discipline capitulate and buy into the hype. Only then comes the sharp correction. This scenario is historically rare — but not impossible. The longest comparable period was 1998–2000: 24 months of dotcom ecstasy, then 30 months of bitter correction.
06What to check now
The 7–20% range is not a theoretical exercise — it's a practical filter for each of your top positions. Four concrete checks:
1. Growth inventory of your top 10. Look at organic revenue growth over the last 5 and 10 years (acquisition- and FX-adjusted). How many of your largest positions sit in the 7–20% zone? For most portfolios this exercise reveals: a meaningful share sits either below 5% (stagnation) or above 25% (hypergrowth with expectation risk). That's not a sell signal — but a conscious observation worth having.
2. ROIC check for all growth names. Growth without ROIC above the cost of capital is stylish capital destruction. Check: is your growth positions' ROIC sustainably above 10–12%? If not, the compounding engine is missing — even at 15% revenue growth.
3. Size-growth consistency. Mauboussin's insight sharpens with size. For your largest positions (≥ $50B market cap): is the expected growth plausible vs. Mauboussin's base rates? If the market prices 20%+ growth over 10 years into a $100B company, that contradicts history.
4. Quality anomaly check. Are your compounders currently «cheaply valued vs. their own history»? If yes, adding is not just defensible but historically rewarded. This is one of those rare periods when discipline is actively paid — not as defensive strategy, but as active return generation.
What disciplined investors do now
They don't chase the narrative. They use the quality anomaly systematically: selectively add to undervalued compounders in the sweet spot, critically examine hype positions with 20%+ growth expectations, gradually trim unconscious stagnation positions (<5%). Over 18–24 months, portfolio quality shifts gradually toward sweet-spot businesses. It's not spectacular, but it's exactly what Buffett did in 1999 while the world dismissed him as «outdated». Math beats mood. Always.
07Frequently asked questions
Should I stop holding hypergrowth stocks altogether?
Not categorically. Selective exposure to hypergrowth names (ideally below 10–15% of portfolio) can make sense when management and business model convince. Important to be aware: such positions are speculation with compounder characteristics, not investment in the classical sense. And: their half-life is structurally shorter. Mauboussin's data is a warning, not an exclusion criterion.
Are the 7 and 20% limits hard rules?
No, they are heuristic. Some quality frameworks use 5–18%, others 8–25%. The exact numbers matter less than the logic: a floor below which the business doesn't keep up with global indices, and a ceiling above which history shows no sustainable durability. The logic is robust, the numbers are guides.
What if a company briefly grows over 20%?
Short-term no problem — the decisive test is durability over 10 years. Many high-quality compounders grow 25–30% in individual years but fall back into the sweet-spot zone on long-term average. That's sustainable. What becomes problematic: valuations that price in 20%+ as base case over 10+ years — Mauboussin's data shows this is statistically rare.
Is the current quality anomaly really as strong as 1999?
Multiple charts (in the NZZ original, chart 5) show: the relative underperformance of quality stocks has reached extremes last seen in 1999. This doesn't mean the pattern will repeat exactly — but it does mean the mean-reversion opportunity is statistically very attractive. Historically, such phases have delivered sharp quality outperformance 12–24 months later.
Read next — the thematic anchors of this analysis
Focus on the Top Line
Top-Line × Margin Expansion — the compounder engine
The Tortoise Problem
Why quality wins — if you stay the course
The Next Kodak Moment Is Coming
Disruption resilience as second quality dimension
Winners Keep Winning
Why quality is persistent
History Does Not Repeat, But It Rhymes
Historical parallels in market cycles
arvy Quarterly Report Q1 2026
Current sector allocation
Waiting is the underrated discipline
Munger's quote — «the big money is not in the buying and the selling, but in the waiting» — is uncomfortably relevant today. Waiting is not passivity. Waiting is active discipline against the seduction of the narrative. Waiting is the conscious decision not to join the hottest hype, even when it dominates the headlines. Waiting is the choice to hold sweet-spot compounders, even as they go sideways for 12 months while others double.
The math is brutally simple. 7% over 20 years triples your capital (excluding ROIC reinvestment). 12% over 20 years multiplies it tenfold. 20% over 20 years would be a factor of 38 — but as Mauboussin's data shows, virtually no one at scale achieves that. And if the 20% drops to 8% in year 12, valuation collapses simultaneously, and the investor lives through years of negative returns. That is the asymmetry defining the sweet spot: between 7 and 20%, the expectation-reality ratio is fair. Below is inefficient. Above is dangerous.
Today's quality anomaly amplifies all of this. Whoever holds sweet-spot compounders with discipline while the market chases nuclear fusion and quantum acts like Buffett in 1999 — unglamorous, boring, supposedly outdated. And will — if history rhymes — represent the difference between capital multiplication and capital destruction three to five years from now. Trees don't grow to the sky. Discipline does.
Original written by Thierry Borgeat, Co-Founder of arvy, for The Market by NZZ. The extended arvy version was reviewed by Patrick Rissi, CFA and Florian Jauch, CFA. Data sources: BCG Analysis, Morgan Stanley Research (Top-Quartile S&P 500 1990–2009), Michael Mauboussin / Credit Suisse («The Base Rate Book — Sales Growth»), Pictet Historical Performance Study Swiss Equities, Gavekal, Goldman Sachs, Bloomberg, Jeff Weniger / Refinitiv, BCA Research. Novo Nordisk reference as historical example, not an individual-stock recommendation. Last update: April 2026.
Disclaimer: This article is for general educational purposes and does not constitute personal investment advice. Security names mentioned are illustrative and not buy- or sell-recommendations. Past performance is no guarantee of future results. Scenarios are assessments, not forecasts. arvy is a FINMA-supervised asset manager with a CISA license (Art. 24). Imprint & Legal Notices.
